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One sentence summary: Variation within Ebola genomes is most common in the intergenic regions and within specific areas of the genes encoding the
glycoprotein (GP), nucleoprotein (NP) and polymerase (L); genomic conservation and epitope prediction, combined with glycosylation sites and
experimentally determined epitopes, can identify the most promising regions for the development of therapeutic strategies.
Editor: Urs Greber
ABSTRACT
The 2014 Ebola outbreak in West Africa is the largest documented for this virus. To examine the dynamics of this genome,
we compare more than 100 currently available ebolavirus genomes to each other and to other viral genomes. Based on
oligomer frequency analysis, the family Filoviridae forms a distinct group from all other sequenced viral genomes. All
filovirus genomes sequenced to date encode proteins with similar functions and gene order, although there is considerable
divergence in sequences between the three genera Ebolavirus, Cuevavirus and Marburgvirus within the family Filoviridae.
Whereas all ebolavirus genomes are quite similar (multiple sequences of the same strain are often identical), variation is
most common in the intergenic regions and within specific areas of the genes encoding the glycoprotein (GP),
nucleoprotein (NP) and polymerase (L). We predict regions that could contain epitope-binding sites, which might be good
vaccine targets. This information, combined with glycosylation sites and experimentally determined epitopes, can identify
the most promising regions for the development of therapeutic strategies.
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INTRODUCTION
The current 2014 Ebola virus disease (EVD) outbreak in West
Africa is the largest in its four decades of history. The outbreak
has dominated the news, inspiring the imaginations of many,
often, unfortunately, in detrimental ways because of fear of the
unknown. In this review, we examine the genomes of the Filoviri-
dae family of viruses to which the genus Ebolavirus belongs, and
compare the ebolavirus genomes to a set of roughly 4000 refer-
ence viral genomes, as well as to the genomes of other genera in
the same virus family. We summarize how the different isolates
of Ebola virus vary amongst the sequenced genomes currently
available, and make some observations that will address basic
questions about how changes in the viral genome might affect
EVD virulence and immune responses, and efforts to defeat it.
‘So, what DO we know about this deadly viral scourge?’ Ap-
proximately 75% of emerging infectious diseases like Ebola are
zoonoses that result from various anthropogenic, genetic, eco-
logic, socioeconomic and climatic factors (Gebreyes et al. 2014).
The current Ebola epidemic inWest Africa is a stark reminder of
the role unknown animal reservoirs play in public health.
We know that in Central Africa, the location of all previous
EVD outbreaks, several monkey species, chimpanzees, gorillas,
baboons, duikers and fruit bats have been found to be infected
with Ebola virus during trapping studies. Given their lack of
overt disease while infected, there is good evidence that various
species of bats, predominantly fruit bats, are significant natu-
ral reservoirs for ebolaviruses,marburgviruses and cuevaviruses
(Olival and Hayman 2014) although the natural hosts for most
ebolavirus species and variants are still unproven, as is still the
case for the current outbreaks.
Transmission of EBOVs from bats and other zoonotic reser-
voirs to humans requires a hierarchy of enabling conditions that
connect the redistribution of reservoir hosts, episodic viral infec-
tions within these hosts, random human exposure to infected
blood or carcasses from these hosts and sufficient susceptibil-
ity of the new recipient human host (Plowright et al. 2015). Two
hypotheses may explain 40 years of temporal and spatial pulses
of Ebola outbreaks: episodic shedding from persistently infected
reservoir hosts or transient epidemics that occur as the virus is
transmitted among reservoir populations during animal migra-
tions.
We know that EBOV’s ability to jump from its natural reser-
voirs to humans and other animals is not new. From 1976,
when an EBOV was first identified as the cause of two out-
breaks of a viral hemorrhagic fever (VHF) that later was known
as EVD, through 2013, the World Health Organization reported
1716 confirmed EVD cases, all occurringwithin documented out-
breaks in tropical regions of Central Sub-Saharan Africa. How-
ever, EBOV probably infected humans many times prior to 1976,
but was unrecognizedwith the tools available at the time among
the many other such VHF diseases in the affected regions of
Africa.
The 2014 outbreaks in West Africa and the Republic of the
Congo are occurring at a time when we have the technology to
rapidly and affordably sequence complete viral genomes inways
previously unimaginable. As technology has improved, blood
samples and viral isolates collected from each of these out-
breaks have been partially or completely sequenced, giving us
an unprecedented opportunity to study the etiology of the virus
related to changes in its genome.
HOW DIFFERENT IS EBOLA FROM OTHER
VIRUSES?
We compared about 4000 complete virus genome sequences
from the RefSeq database of viral sequences (downloaded 6 Au-
gust 2014), and added additional available genomes from the
family Filoviridae in GenBank. Figure 1 shows a dendrogram of all
these viral genomes, which was based on 9-bp K-mer frequency
analysis andwas constructed using the feature frequency profile
(FFP) method (Jun et al. 2010).
One should be cautious about interpreting this figure. It
is easy to assume that this is a ‘phylogenetic tree’, repre-
senting evolutionary distances between the viruses. However
tempting, this dendrogram is NOT in general reflective of over-
all phylogeny. This tree contains viruses from all sequenced
families, but there is not a single gene conserved amongst
all viruses on which phylogeny could be based. So this fig-
ure is to be interpreted as roughly representing ‘genome dis-
tance’, based on similarity of (frequency of) 9-mers. Having said
that, the deep branches that are observed for the virus fami-
lies are as would be expected—most of the viral families are
quite different from each other, and these often form clear
clusters, including the family Filoviridae, shown in red. An in-
teractive, zoomable version of this figure is available online
(http://dtree.ornl.gov/ebola ref 9mer.html).
HOW DIFFERENT IS THE GENUS EBOLAVIRUS
FROM OTHER FILOVIRUSES?
The order Mononegavirales, family Filoviridae, genus Ebolavirus,
has five species: Zaire ebolavirus (EBOV), Taı¨ Forest ebolavirus
(TAFV), Reston ebolavirus (RESTV), Sudan ebolavirus (SUDV) and
Bundibugyo ebolavirus (BDBV). The taxonomy of the order
Mononegavirales is described in detail in the Supplementary
material.
In humans, EVD is caused by four viruses: EBOV, TAFV, SUDV
and BDBV. The fifth ebolavirus, RESTV, is not known to cause
disease in humans, but does cause EVD in non-human pri-
mates. EBOV is the most virulent of the viruses in humans and
is responsible for the largest number of outbreaks and for the
largest number of cases. Major EBOV outbreaks with 100 ormore
cases occurred in Yambuku, Zaire (now Democratic Republic of
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Figure 1. A dendrogram of all viral genomes from RefSeq complemented with, in red, multiple genomes in the family Filoviridae extracted from GenBank. The dendro-
gram is constructed by the FFP method which is based on K-mers, with K set to 9, in the moderate range of optimal feature length based on analysis of cumulative
relative entropy and relative sequence divergence as described previously in Wu et al. (2009).
the Congo—DRC), in August 1976 (Pattyn et al. 1977); in Kikwit,
Zaire, in 1995; in the Republic of the Congo (ROC—also known as
Congo-Brazzaville) and Gabon, in 2001–02 (Nkoghe et al. 2005); in
Lossi, ROC, in 2003; in Bamoukamba, DRC, in 2007; and in West
Africa (Guinea, Sierra Leone and Liberia) in 2014–15. A smaller
outbreak occurred in Ikanamongo, DRC, in 2014, concurrentwith
the West Africa outbreak.
SUDV was responsible for the first recorded case of EVD,
during a major outbreak in Nzara Sudan in June 1976. The
first international response, however, did not occur until two
months later for the Yambuku outbreak, which gave the virus
its name, taken from the nearby Ebola river. Another signifi-
cant SUDV outbreak occurred in Gulu, Uganda, in 2000–01. BDBV
has been responsible for two outbreaks, a major outbreak in Ka-
bango, Uganda, in 2007 and a smaller outbreak in Isiro, DRC, in
2012.
The only known infection in humans by TAFV occurred
in 1994 during an epizootic VHF event among western chim-
panzees in the Taı¨ National Park of Coˆte d’Ivoire. A scientist
performing necropsies on infected chimpanzees contracted EVD
but survived. Comprehensive descriptions of all known EVD out-
breaks can be found in Corum (2014), Mylne et al. (2014) and CDC
Outbreaks Chronology (2015).
None of the viruses in the six EBOV outbreaks over the last
40 years have had clinical conditions unique enough to warrant
designating any as new ‘strains’; therefore, they are called vari-
ants, using the following ICTV Virus nomenclature template:
〈virus name〉 / (〈strain〉) / 〈isolation host-suffix〉 / 〈country of
sampling〉 / 〈year of sampling〉 / 〈genetic variant designation〉 -
〈isolate designation〉 (Kuhn et al. 2014).
The EBOV variant responsible for the 2014 West African out-
break has been named EBOV Makona (phonetic: mah-kaw’-nuh
or muh-koh’-nuh) after the Makona River close to the border
between Liberia, Guinea and Sierra Leone where the current
outbreak originated (Kuhn et al. 2014) several thousand kilome-
ters away from the DRC. In late 2014, EVD also broke out in the
Boende District of the DRC. All cases were associated with one
variant, for which the name ‘Lomela’ (law-me’-lah) has been
proposed, after the Lomela River that runs through the DRC’s
Boende District (Kuhn et al. 2014).
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Figure 2. Amaximum likelihood tree based on complete genomes of the three filovirus genera. The three generaMarburgvirus, Cuevavirus and Ebolavirus are separated
and genus Ebolavirus is further split into species, indicated on the right. The tree was produced with PhyML (Guindon et al. 2010) with the GTR + I + G nucleotide
substitution model to a multiple sequence alignment of complete genome sequences by MAFFT (Katoh and Standley 2013). The best substitution model was identified
by jModelTest (Guindon and Gascuel 2003; Darriba et al. 2012) among a broad suite of evolutionary models based on BIC. The numeric values represent the number of
members within the clades.
As previously stated, filoviruses belong to the order Monone-
gavirales, which, as the name suggests, are non-segmented
negative-sense, single-stranded RNA viruses that have inverse-
complementary 3′ and 5′ termini (Pringle 2005). In addition to the
genus Ebolavirus, the family Filoviridae contains the genus Mar-
burgvirus, first described in Marburg, Germany, in 1967 (Siegert
et al. 1967), and the genus Cuevavirus, first isolated from dead
bats in Asturias, Spain, in 2002 (Negredo et al. 2011).
There is a strong similarity of genomic structure across
the family Filoviridae, which points to a potential com-
mon origin. The presence of endogenous viral sequences
in numerous mammalian genomes suggests that a common
Ebola/Marburg/Cuevavirus-like ancestral virus existed between
32 and 53 million years ago (Belyi, Levine and Skalka 2010). The
ebolaviruses and cuevaviruses diverged frommarburgviruses at
least 5 million years ago during the Miocene (Taylor et al. 2014).
As natural reservoirs for ebolaviruses, marburgviruses and
cuevaviruses, infected bats are typically asymptomatic (al-
though there have been occasional die-offs), suggesting stable
host–virus relationships that have evolved overmillions of years
(Wynne and Wang 2013; Olival and Hayman 2014). The stability
of this host–virus balance is illustrated by the relative similar-
ity of EBOV sequences from the 1976 Yambuku outbreak to the
sequences from the 2014 West Africa and DRC outbreaks; the
genomes from the 1976 outbreak are, on average, 97% identical
to the 2014 West Africa outbreak and 99% identical to the 2014
DRC outbreak.
To understand the global relationship between the three gen-
era of the family Filoviridae, we constructed a maximum likeli-
hood tree based on complete genomes of all 80 marburgvirus
genomes, the only available complete cuevavirus genome, and
84 non-redundant ebolavirus genomes (Fig. 2). Descriptions of
the ebolavirus and marburgvirus genome datasets are given
in the Experimental Procedures section. As can be seen in
Fig. 2, ebolaviruses separate into the five recognized species:
Bundibugyo ebolavirus, Reston ebolavirus, Sudan ebolavirus, Taı¨ For-
est ebolavirus and Zaire ebolavirus.
The single species of the genus Marburgvirus (Marburg mar-
burgvirus) contains two groups, Marburg virus and Ravn virus,
whose distinction is shown in the marburgvirus clade in
Fig. 2. All three filovirus genera and all five of the ebolavirus
species appear to be monophyletic. Genus Cuevavirus is more
closely related to genus Ebolavirus than to genus Marburgvirus,
in agreement with previous work (Carroll et al. 2013). The Reston
genomes are grouped with Sudan genomes, and Taı¨ Forest with
Bundibugyo. The Zaire genomes share a common ancestor with
a clade of the Taı¨ Forest and Bundibugyo genomes first, and then
with a clade of Reston and Sudan genomes.
Genomic structure of the EBOVs
All of the filovirus genomes sequenced to date are about 19 Kb in
length and all encode seven predicted viral proteins, as shown
in Fig. 3A; cuevavirus contains a potential extra open reading
frame in the opposite direction, for which translation has not
been verified, that overlaps for 29 bases with the VP24 gene.
The seven functional proteins encoded in EBOV are
designated as NP (nucleoprotein), viral proteins (VP) VP24
(membrane-associated protein), VP30, VP35 (both polymerase
matrix proteins), VP40 (matrix protein), L (RNA polymerase) and
GP (glycoprotein) (Mu¨hlberger 2007). Each of these genes en-
codes a single protein product, with the exception of GP, which
also encodes sGP and ssGP, as a result of mRNA editing. VP40 is
the primary EBOV matrix protein and regulates assembly and
egress of infectious EBOV particles. VP40 assembles on the inner
leaflet of the plasma membrane of human cells to regulate viral
budding (Soni et al. 2013; Adu-Gyamfi et al. 2014).
In ebolaviruses and cuevaviruses, the GP gene encodes three
proteins of different sizes: the full-length 676-residue surface
glycoprotein GP1,2 (GP for short), which mediates virus–host cell
attachment and fusion, the 364-residue pre-formof secreted gly-
coprotein (pre-sGP) and the 298-residue small secreted glyco-
protein (ssGP) of unknown function. The various glycoproteins
are produced from frameshifts as a result of mRNA editing of a
polyadenosine site (Lee and Saphire 2009; Finn, Clements and
Eddy 2011). Transcripts containing seven adenosine residues
(without mRNA editing) encode pre-sGP, while addition of a sin-
gle A residue at the RNA editing site results in GP, and addition
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Figure 3. Gene organization of filovirus genomes and pan-core proteome analysis. (A) Gene organization of viruses from generaMarburgvirus, Ebolavirus and Cuevavirus.
Conserved regions are indicated by color, with striped color for weak conservation. The furin cleavage site for glycoprotein GP is indicated by the inverted Y-shaped
symbol. Gray blocks below the line indicate the position of conserved functional domains (predicated by InterProScan; Jones et al. 2014). (B) Venn diagram summarizing
the results of the pan-core analysis based on protein sequence alignmentswith a cut-off based on the 50–50 rule (see the text). (C) Venndiagramof the protein functional
domains resulting from pan-core analysis based on HMM.
of two A residues results in ssGP (Volchkov et al. 1995; Sanchez
et al. 1996). Deep sequencing of mRNA in ebolavirus-infected
Vero cells found approximately 70% of reads with 7 As, 25%with
8 As, 2% with 9 As and 2% with 10 As. Cell culture passaging
studies have shown that GP with 8 As is the primary functional
translation product (Shabman et al. 2014). Full-length GP protein
is post-translationally cleaved by cellular proteases such as fu-
rin at position 511 to produce GP1 and GP2, which are covalently
linked in the mature GP1,2 complex. Protein sGP, which can have
immunogenic properties, is produced as pre-sGP (364 amino acid
residues), which then undergoes post-translational proteolytic
cleavage at position 324 by furin to yield soluble sGP.
Pan-core proteome analysis was performed using all 73 mar-
burgvirus proteomes, the single cuevavirus proteome and 53
non-redundant ebolavirus proteomes, including only the largest
GP (the 676-residue surface glycoprotein) for cuevaviruses and
ebolaviruses. Descriptions of the ebolavirus and marburgvirus
proteome datasets are given in the Experimental Procedures
section. All proteins were clustered using USEARCH (Edgar 2010)
with a cut-off of 50% minimum sequence identity over at least
50% of the longest sequence length. This resulted in 19 pro-
tein clusters, each of which corresponded to a different pro-
tein type. The results are summarized in the Venn diagram
of Fig. 3B. All protein types of marburgviruses were found
in separate clusters, while there were five singleton clusters
unique to cuevaviruses and four clusters unique to ebolaviruses.
The three clusters that were composed of proteins from both
ebolaviruses and cuevaviruses contained VP35, VP24 and L.
Thus, despite the conservation in gene organization observed
with all filovirus genomes, only ebolaviruses and cuevaviruses
share significant sequence similarity above the 50–50 cut-off.
However, the underlying functional domains for all seven pro-
teins are conserved across all the genomes from the fam-
ily Filoviridae, when these domains were compared by Hid-
den Markov Model (HMM) analysis (Finn, Clements and Eddy
2011), as illustrated in Fig. 3C. The likely explanation for this
difference is that viral genomes evolve relatively fast—hence,
the protein sequences have varied substantially, to the point
that by using standard cut-off values, the marburgvirus pro-
teins appear non-conserved, despite their functional domain
conservation.
We crosschecked the existing functional domains of the eight
proteins against the RefSeq virus protein database derived from
about 4000 viruses. Most of the domains (based on InterPro
functional domain identification; Hunter et al. 2009) are not
found in other viruses. Two functional domains, IPR014023 and
IPR026890, within the RNA-dependent RNA polymerase L gene
were found in 90 other viruses.
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Figure 4. A maximum likelihood tree of 60 Zaire ebolavirus genomes. The tree was produced with the GTR + G model rooted by a clade of the 1976 outbreaks. All
isolates were of human origin, with the exception of two isolates from the 1976 outbreak (AF499101 wasmouse adapted, EU224440 was from a Guinea pig). The asterisk
identifies the DRC 2014 isolate within a clade of 1994–1996 isolates from Gabon. The numbers on the major internal branches represent bootstrap support (%) out of
100 replicates. Abbreviations: DRC, Democratic Republic of Congo; GAB, Gabon; GIN, Guinea; SLE, Sierra Leone.
HOW DIFFERENT ARE THE EBOLAVIRUSES IN
THE CURRENT OUTBREAK FROM THOSE OF
PREVIOUS EBOLA OUTBREAKS?
Using the same approach as described in Fig. 2, we constructed
a maximum likelihood tree of 60 Zaire ebolavirus genomes (see
Experimental Procedures section), including 34 sequences ob-
tained from isolates of the 2014 West Africa outbreak, this time
using the GTR + G nucleotide substitution model as the best
model. We rooted our tree of species Zaire ebolavirus to the clade
of the earliest recorded outbreak, which corresponds to the 1976
outbreaks (Fig. 4). The inference of the root is described in the
Experimental Procedures section. This analysis resulted in clus-
ters containing isolates from five distinct periods: 1976, 1994–
96, 2002, 2007–08 and 2014, each representing a different unique
outbreak. The tip labels of the tree describe, in order, features
of accession, strain, country, host (only if non-human) and col-
lection date according to metadata available from the European
Bioinformatics Institute and the National Center for Biotechnol-
ogy Information, confirmed by a literature survey.
The Zaire ebolaviruses can be separated into clades, rep-
resenting outbreaks in Central Africa (DRC and Gabon) and
West Africa (Guinea, Sierra Leone and Liberia) showing distinct
geographical and temporal clustering. Zaire ebolaviruses from
DRC separate into three clades, corresponding to different time
periods. One of these clades is grouped with a Gabon clade
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Figure 5. Atlas of the genome of ebolavirus KJ660347, showing, from the outer ring inwards, variations within 84 other ebolavirus genomes, structural cruciforms and
palindromes (van Noort et al. 2003), the coding sequences, local inverted repeats, palindromic hexamers, simple repeats and AT content. The conservation percentage
(%) is defined as the number of genomeswith the same letter on amultiple sequence alignment normalized to range from 0 to 100% for each site along the chromosome
of Ebola KJ660347.
collected during the years 1994–96. The outbreak that occurred
late in the summer of 2014 in the vicinity of Boende Town in
DRC groups with a set of previous Gabon outbreak genomes iso-
lated 20 years earlier, but not to the genomes of intervening
outbreaks in that country. The 2014 DRC isolate is also clearly
distinct from the large West African 2014 outbreak, as has been
observed before (Maganga et al. 2014). The current West African
2014 outbreak, from which the majority of sequences are de-
rived, is well documented to have originated in Guinea and
subsequently spread to Sierra Leone and Liberia. From there,
travelers involuntarily exported the virus to additional coun-
tries as single cases or as patients were relocated for care. The
2014 West African group forms a distinct clade, instead of be-
ing nestedwithin the previous Zaire ebolavirus outbreaks,which
suggests that the current outbreak in the West Africa is caused
by a divergent lineage of Zaire ebolaviruses (Dudas and Rambaut
2014).
So far, we have focused on complete genomes to study the
Ebola outbreak, which mostly correspond to human isolates.
However, many Ebola studies published before the 2014 out-
breaks used mainly partial genomes obtained by sequencing
gene PCR products (Wittmann et al. 2007). To be as comprehen-
sive as possible in our study, we included a set of 21 full or partial
sequences encoding GP deposited by Wittmann et al. (2007). We
also included sequences encodingNP, amongwhichwere 12 par-
tial genes of viruses isolated from wild apes (i.e. EU051639 and
EU051639), each covering about 65% of the complete CDS of the
NP gene. After alignment, the complete sequences were short-
ened so that only matching regions remained. The resulting
maximum likelihood trees for GP andNP are available in Fig. S1A
and B (Supporting Information). Both trees show branching pat-
terns very similar to the one shown in Fig. 4. The additional
NP proteins from Gorilla isolates (collected in Gabon between
2001 and 2005) form a monophyletic group with the other hu-
man isolates collected during this period. The inclusion of addi-
tional GP sequences results in a more complex picture of molec-
ular evolution of Zaire ebolaviruses. The isolates from animals
clustered together with 100% bootstrap support, but show a dis-
tinct evolutionary distance unlike the current outbreaks of hu-
man isolates. Both the NP and the GP analysis grouped a 2002
outbreak of strain Ilembe in Gabon with a clade of animal iso-
lates from the same country. The Gabon outbreaks fall into two
clades; one is placed in such a way that the tree topology agreed
with the temporal pattern of Zaire ebolaviruses, but the other
clade, including the animal isolates (Gorilla, Chimpanzee) from
between 2001 and 2005, is placed between two clades of 2007–
08 DRC outbreaks and the current outbreak in West Africa, vi-
olating a temporal arrangement with the bootstrap support of
66%. Inclusion of GP coding genes from zoonotic viruses in the
analysis might imply a transmission route through a potential
connection between the current human infection in Guinea and
Sierra Leon and an infection in animals in Gabon more than
10 years ago, even though at first this seems unlikely because of
the geographical distance between the two outbreaks. However,
a long-distance migration of infected bats might explain the
anomaly.
IS THE CURRENT OUTBREAK STRAIN OF
EBOLAVIRUSES ‘RAPIDLY EVOLVING’?
Figure 5 maps the sequence conservation along the chromo-
some of one reference ebolavirus genome, comparing it to all
of the other genomes sequenced to date. As can be seen from
the outer ring, the intergenic regions and parts of the GP en-
coding region have much less conservation (that is, a higher
mutational frequency) than the regions encoding the internal
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Figure 6. Multiple sequence alignment of a portion of the ebolavirus glycoprotein (GP) from four species of ebolavirus genomes, showing identities between the Taı¨
Forest genome (gi|208436395) and three others (numbered using the Zaire ebolavirus genome of gi|208436395). Identities between Taı¨ Forest and others are shaded in
gray. At each position of the alignment, the genome with the highest identity to Taı¨ Forest GP is shown above the alignment by color and the first letter of the genome
type: Z = Zaire, gi|667853009 (green), S = Sudan, gi|165940954 (cyan), and R = Reston, gi|253317719 (yellow). The highest similarity at each position was determined by
the largest number of identities in a five-residue window centered at each location, with dashes indicating a tie or an undetermined result. Dashes between blocks of
the same letter are colored by the surrounding color.
viroid proteins. This finding is consistent with the structurally
constrained relationship among proteins that are integrally in-
volved in fitting and working functionally together, and it pre-
dicts this patchwork of mutability. The membrane-protruding
glycoprotein GP is less constrained, and there is even a poten-
tial advantage to external antigen/epitope variability for escap-
ing host defenses and gaining new cellular receptor tropisms,
allowing better adaptations to new hosts.
It has been suggested (Wittmann et al. 2007) that RNA nega-
tive strand viruses may undergo recombination of genetic ma-
terial, noting that contradictory evolutionary tree relationships
among the strains derived from specific sites in ebolavirus pro-
teins can show different relationships. We examined this hy-
pothesis, focusing on a region of surface protein GP, which
is known to evolve more rapidly than the other proteins.
Figure 6 indicates, in the context of a multiple sequence align-
ment, that a mosaic pattern exists in GP—that is, sequences in
different regions of the protein cluster differently than the full-
length protein. The block surrounding the GP furin cleavage site
highlights the similarity of this region in TAFV GP to that of the
Zaire ebolavirus, while the region from residue 380–425 shows a
much higher similarity to the SUDV. The general mosaic struc-
ture of this alignment is not consistent with a model in which
evolution is happening with equal frequency along the length
of the protein. Different parts of the protein are evolving at di-
vergent rates—perhaps due to the selective pressure variability
along the protein sequence—which in some cases could provide
selective immune system advantage.
Based on palindrome predictions (van Noort et al. 2003),
there are many loci on the chromosome that contain quasi-
and perfect palindromes, as shown in Fig. 5. Some of these are
located at the beginning and end of genes. Palindromes can
form hairpin loop structures in the RNA transcript that might be
similar to the initiation step of microRNA (miRNA) biogenesis
found in the host. The virus hairpin transcript might be cleaved
off to become pre-miRNA and eventually become mature
miRNA via the host Drosha and Dicer proteins, respectively.
The mature virus miRNA could thus play an inhibition role on
expression of host genes.
Indeed, Liang et al. (2014) have recently identified two
pre-miRNAs derived from the EBOV genome and conserved
among different EBOV strains. These pre-miRNAs were pro-
cessed through the host’s cellular Dicer processing machinery
into mature miRNAs. Liang et al. have also predicted potential
target genes for the regulatory function of these miRNAs and
their possible immunomodulatory functions in EVD. EBOV may
produce thesemiRNAs in abundance early in an infection,which
could serve as non-invasive early biomarkers for the diagnosis
and prognosis of EBOV infection and as therapeutic targets for
Ebola viral infection treatments.
From the host side of miRNA involvement in viral
pathogenicity, Sheng et al. (2014) recently showed that hu-
man umbilical vein endothelial cells that overexpress EBOV
GP undergo cell detachment and rounding; GP expression
caused at least 18 different host cell miRNAs to be differentially
expressed. Knock-down experiments with specific miRNA
inhibitors showed that three of the induced host miRNAs were
essential for mediating the EBOV GP-mediated cell damage.
HOW SIMILAR ARE PHYLOGENETIC TREES
CONSTRUCTED FROM DIFFERENT FEATURES
(DNAs, PROTEINS) OF EBOLAVIRUSES?
The DNA sequence variations observed in Fig. 5 indicate differ-
ent degrees of variation at different loci of the EBOV chromo-
some. We investigated these differences by comparing topol-
ogy of phylogenetic trees constructed from different features. A
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Table 1. A summary of substitution models used for the ebolavirus trees comparison in Fig. 7.
Feature Substitution Feature Substitution
Whole genome GTR + I + G VP30 protein JTT + G
NP coding gene GTR + I + G VP24 protein JTT + G
VP35 coding gene HKY + I + G L protein FLU + I + G + F
VP40 coding gene HKY + G Intergenic: - NP HKY + G
GP coding gene GTR + I + G Intergenic: NP-VP35 HKY + I
VP30 coding gene HKY + I + G Intergenic: VP35-VP40 HKY + I
VP24 coding gene GTR + G Intergenic: VP40-GP HKY + I
L coding gene GTR + I + G Intergenic: GP-VP30 HKY + G
NP protein JTT + G Intergenic: VP30-VP24 HKY + G
VP35 protein JTT + G Intergenic: VP24-L HKY + G
VP40 protein JTT + G Intergenic: L- HKY + G
GP protein FLU + G
Figure 7. Ebolavirus trees comparison. This is an image plot of branch score
distances between alignment-based trees constructed by different features in-
cluding whole genome alignment (WGA), coding gene sequences (CDS), inter-
genic (IG) sequences, protein sequences and three alignment-free-based whole
genome trees by FFP, NRD and RPD.
minimum dataset consisting of 53 non-redundant Ebola
genomes was used for the tree comparison. We constructed
maximum likelihood trees based on whole genomes, coding
genes, intergenic regions and individual proteins, which, in to-
tal, led to 23 different alignment-based trees. The substitution
models identified as the best model for each feature are listed
in Table 1 in the Experimental Procedures section. We con-
structed three more trees by applying BIONJ (Gascuel 1997) to
distance matrices of whole genomes generated by alignment-
free approaches—the FFP method with K = 11, Repeating Pat-
tern Distance (RPD) (described in Experimental Procedures sec-
tion) and Normalized Compression Distance (NCD) (Rosa et al.
2008; Ito, Zeugmann and Zhan 2010). Figure 7 is an image plot of
branch score distances (Kuhner and Felsenstein 1994) between
the various trees, where the branch score distance is defined as
the sum of the squares of the differences between each branch’s
lengths in the two trees, if it is found in both trees. If a branch is
found only in one tree, then a branch of length 0 is considered
to exist in the other tree. The NCD approach resulted in the tree
topology most distant from maximum likelihood trees. Except
for the intergenic region between VP35 and VP40, all intergenic
regions showed tree topology relatively different from trees of
coding genes and proteins. Again, the glycoprotein tree showed
the highest variability among individual protein trees. The gly-
coprotein nucleotide tree and GP coding sequence tree best cap-
tured the topology of an alignment-based whole genome tree,
implying that GP may be indicative of molecular evolution of
ebolavirus genomes.
HOW CAN BETTER VACCINES BE DEVELOPED
FOR EVD?
The virulence of Ebola is extreme, at the heart of which is a
multi-layered evasion of the host’s immune system (Wong et al.
2014). The evasion strategies include the downregulation of type
I interferon production, the masking of viral epitopes and the
abundant expression of secreted sGP, which overloads the host’s
adaptive humoral immunity (Wang, Liu and Dai 2014). By these
mechanisms, the specific and non-specific host antiviral im-
mune responses that normally limit viral replication are inef-
fective, so that a rapid increase in viral load can quickly result
in death. Four of the proteins EBOV produces have been shown
to interact with the host in ways that counteract the host’s im-
mune response. VP35 is capable of capping dsRNA and interacts
with IRF7 (interferon regulatory factor 7) to prevent detection of
the virus by immune cells; VP24 interferes with the production
of interferon (IFN) and with IFN signaling in infected cells; GP1,2
protein has shown anti-tetherin activity and the ability to hide
cell-surface proteins (Audet and Kobinger 2014). The main role
of soluble sGP is still unclear, but it is reportedly capable of sub-
verting the anti-GP1,2 antibody response. In addition, as pointed
out before, pre-miRNAs canhave immunomodulatory functions.
The best long-term approach for dealing with EVD is the de-
velopment of reliable and broad vaccines that increase the pro-
portion of resistant individuals in key populations at risk, ei-
ther to prevent future outbreaks or to ensure they are more eas-
ily containable. However, little is currently known about human
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antibody targets for Zaire ebolaviruses and about whether the
observed ongoing genetic drift will affect their roles as immuno-
genic targets. The goal of recent research efforts is to produce
more effective vaccines, those that produce copious amounts
of potent virus-inactivating antibodies and a persistent long-
term broad-spectrum immunity to the current strain of species
Zaire ebolavirus. Ideally, this immunity would extend to other
ebolaviruses. To help achieve this goal, we need to be able to
better predict viral epitopes to use as vaccine materials that will
result in the production of desirable human immune responses.
Microarray analysis recently identified antigens for NP, VP40
and GP from isolates that represented the six known species
of filoviruses (Kamata et al. 2014). This work was extended
with antibody responses in rhesus monkeys vaccinated with
virus-like particles bearing these epitopes, followed by a chal-
lenge with MARV or EBOV. These findings showed an increase
in immunoglobulin G (IgG) as a result of the immunization,
though the antibody response that resulted from a rechallenge
was far more extensive. Moreover, cross-reactivity was observed
between antibodies raised against NP and VP40 of the five
Ebolavirus species, but antibodies against GP were strain specific
(Kamata et al. 2014).
Recovery of infected EVD patients is associated with an ef-
ficient EBOV-specific humoral IgG response, whereas fatal out-
come is apparently the result of insufficient immune responses.
Becquart et al. (2014) identified specific B-cell epitopes in EVD
patient sera for the four EBOV proteins GP, NP, VP40 and VP35.
They also tested EBOV IgG-positive sera from asymptomatic in-
dividuals (EBOV sero-positive with no memory of an infection)
and from symptomatic survivors, comparing sera from the early
humoral response (7 days after the end of symptoms) with the
latememory phase (7–12 years post-infection). Surprisingly, they
found that serum from asymptomatic individuals more strongly
reacted to VP40 than to GP, NP or VP35, suggesting that a vaccine
made with VP40 might be more protective than vaccines from
the other viral proteins. In support of this hypothesis, anti-EBOV
IgG from these asymptomatic patients targeted three regions of
VP40 that were reported to play a crucial role in virus assem-
bly and budding. In contrast, serum from the early humoral re-
sponse of survivors of three EBOV outbreaks reactedmainlywith
GP peptides. These observations, and the fact that GP appears to
evolve faster than the other genes of EBOV, suggest that GP may
not be the only suitable target for vaccine development; among
the other EBOV proteins, at least VP40 should be considered a
potential vaccine candidate.
A closer look on GP epitopes: humoral responses
and experimentally verified B-cell epitopes
The surface glycoprotein GP1,2 is usually considered the target
of choice for antibody production and vaccine research, since
it is the only viral protein exposed on the surface of the virion;
GP1,2 is also the most immunogenic of the EBOV antigens, as de-
termined by DNA vaccine studies that expressed various EBOV
antigens (de La Vega et al. 2015). Recombinant GP1,2 as a vaccine
component induces a broad immune response, both at the cel-
lular and humoral level. However, heavy glycosylation of GP1,2
shields the virus through epitope masking (reviewed by de La
Vega et al. 2015), thus counteracting the host immune response.
Soluble sGP, which is more abundant than GP, forms a disulfide-
linked 110 kDa homodimer, whose role was recently reviewed
(de La Vega et al. 2015). sGP is antigenetic, as antibodies react-
ing with sGP have been observed in the sera of human EVD sur-
vivors; moreover, sGP was able to inhibit the virus-speciffic neu-
tralizing activity of some GP antisera (de La Vega et al. 2015). In-
deed, when vaccines based on both GP1,2 and sGP were tested
in amousemodel, the elicited antibodies cross-reacted between
the two proteins, which is not surprising since they share a com-
mon N-terminus. It has been hypothesized that sGP plays a role
in controlling host humoral immune responses by adsorbing an-
tibodies elicited against GP1,2 (de La Vega et al. 2015).
ZMAb, the highly experimental drug, which has been used
to treat several care workers stricken with EVD, consists of three
mouse antibodies, 1H3, 2G4 and 4G7, whose GP epitope-binding
properties have been reported by Audet et al. (2014). The antibod-
ies 2G4 and 4G7 were shown to cross-inhibit each other in vitro
and probably recognize the same epitope, as they both selected
for the same escape mutation at amino acid position 508 of GP.
The 1H3 antibody selected an escape mutant at amino acid 273
(Audet et al. 2014).
Serological evidence from surviving patients reveals infor-
mation on B-cell responses to epitopes that are active during
infection. So far, the sparse available information indicates that
neutralizing antibodies found in the blood of surviving victims
react to four proteins: NP, VP30, VP40 and GP (Sobarzo et al. 2013).
We focus here on GP, since vaccine development has tended
to concentrate on this protein. To investigate the potential for
vaccine therapeutic approaches, we combined experimentally
mapped B-cell epitope data for GP from a number of experimen-
tal studies (Wilson et al. 2000; Shahhosseini et al. 2007; Takada
et al. 2007; Lee et al. 2008a,b; Bale et al. 2012; Becquart et al. 2014;
Lennemann et al. 2014; Qiu et al. 2014; Wang, Liu and Dai 2014).
Certain sites, such as in the center of the mucin domain near
amino acid 400 and around amino acids 480–500, just prior to
the furin site, are identified in four or more independent studies
and are also consistent with sera-recognized epitopes in Ebola
patients.
Figure 9 shows a diversity of epitope locations identified in
various studies, perhaps reflecting differences in the structure
and sequence of GP from various Ebola strains, as well as differ-
ences in the hosts inwhich the studieswere done. Inmost cases,
animal studies were used, but some data from human patients
are included. Themost consistently recognized region of GP is in
the middle of the protein, around residues 390–412, where four
experimental studies find epitopes and two Ebola patients had
mapped epitopes. These amino acid residues lie in uncleaved GP
or in GP1 in the center of themucin domain. This region is disor-
dered in crystal structures but is positioned where it is accessi-
ble outside the Ebola membrane (Lee et al. 2008a). Additionally,
a region from about residues 480–500 seems to be strongly rec-
ognized in several studies. This region is just prior to the furin
cleavage site that cleaves the long GP precursor into GP1 and GP2.
Portions of the GP glycan cap region (fromabout residue 227–313)
are recognized in only one study, but was found in two patients
(Becquart et al. 2014).
Predicted T-cell epitopes
In addition to humoral immunity, mediated by B cells, another
essential arm of the host adaptive immune response is cellular
immunity, mediated by T cells. T cells interact with small pep-
tide fragments displayed on the surface of cells in complex with
Major Histocompatibility Complexes, MHC (human leukocyte
antigens, HLA in humans). Generally speaking, two main types
of T cells exist; cytotoxic T cells (CTL) and helper T cells. Like-
wise, two types of MHC molecules exists; class I that presents
peptides to CTLs, and class II that presents peptides to helper
T cells. MHC class I molecules present peptides derived from
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mapped data, where the epitope was not well localized within 50 amino acids, were omitted.
inside the cell, and MHC class II molecules present peptides de-
rived from endocytosed proteins. As the target of both types of T
cells is a peptide bound to anMHCmolecule, binding toMHC is a
necessary prerequisite for a peptide to induce a T-cell response.
While factors other than MHC binding can dictate whether a
peptidewill end up being an epitope (i.e. be able to induce a T-cell
response), several studies have demonstrated that MHC binding
is the single most selective step in the T-cell antigen presenta-
tion process (Yewdell and Bennink 1999; Stranzl et al. 2010; Trolle
and Nielsen 2014).
T-cell epitopes were predicted for both MHC class I and
MHC class II MHC molecules for the ebolavirus proteome using
the software described in the Experimental Procedures section.
Since the immune response of the human population in West
Africa and in the United States (US) is likely/known to differ
(caused by variations in theMHC), this was accounted for by fac-
toring in allele frequency data for Caucasians, Hispanics, African
Americans, Asians and Native Americans for US population. A
total of 3000 potential epitopes were predicted for class I binding
and 4500 for class II. From these epitopes, selections were made
for each population (US andWest Africa), 10 peptideswith strong
predicted MHC class I binding properties, and 10 peptides with
strong predicted MHC class II binding properties, that in com-
bination could be expected to produce an immune response in
both populations under study, covering all the ebolavirus vari-
ants included in this analysis. The selection for class I contained
seven strong epitopes in common between the two populations
(four in protein L, and one each in GP, NP and VP40), and three
that differed in each of these human populations. Of the 13 dif-
ferent epitopes selected for class I, 7 were found in the L pro-
tein and none were detected for VP24. For MHC class II peptide
selection, there were six predicted strong epitopes in common
between the West African and US populations (four in NP, and
one each in VP24 and GP). Two more epitopes (one in protein
L and one in GP/sGP) were shifted by one amino acid only be-
tween the West African and US populations; these pairs were
also interpreted to be conserved epitopes for the two popula-
tions. Population-specific epitopeswere identified for VP24 and L
(West African only) and for VP40 andGP (US only). That produced
12 different class II epitopes, in which NPwas slightly overrepre-
sented (4 out of 12 epitopes). The data are summarized in Tables
S1 and S2 (Supporting Information).
Next, we mapped the epitopes along the respective
ebolavirus protein sequences in Fig. 8. This revealed that
for NP three of the four class II epitopes that were predicted to
be recognized in the combinedWest African and US populations
were overlapping. This region positioned at amino acid 199–217
thus seems to bear a strong signal for MHC class II, in both
populations under study. This same region was also recognized
as an MHC class I epitope (for US population only).
Figure 8 also displays the observed variability in protein al-
leles for the location of the epitopes. Our model predicts that
all the observed variant epitopes within NP maintain a similar
HLA-binding profile (data not shown). A similar mapping exper-
iment identified that the three predicted epitopes listed for VP40
(two for class I and one for class II) were also overlapping, at po-
sition 153–180. However, at least one variant of ebolavirus VP40
exists with an alternative amino acid sequence that abolishes
binding to HLA (Fig. 9B). The three epitopes identified for sGP
(secreted spike glycoprotein) are distributed at three different
locations, and although none of them are 100% conserved in the
GP protein sequences of various ebolavirus strains, all analyzed
variants share a similar HLA-binding profile (data not shown).
For protein VP24, two epitopes are separated by 20 amino acids,
while for protein L, most class I epitopes are located between
amino acid 526 and 563. This region also contains an overlapping
epitope forMHC class I and class II (Fig. 9E). For the predicted epi-
tope in L located closest to the carboxyl end of the protein, an
alternative protein sequence exists that was predicted to have
lost its HLA-binding potential (data not shown). Finally, two epi-
topes were mapped next to each other for VP35, of which the
MHC class I epitope is completely conserved, while variations in
class II epitope maintain a similar HLA class II binding profile
(data not shown).
Theoretical prediction of epitopes that could serve as vac-
cine candidates should take available information on se-
quence variation between virus strains into account, as well
as variation in population responses. Our predictions identified
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Figure 9. Position of 10 predicted MHC class I (red) and 10 class II (blue) epitopes in six ebolavirus proteins, and the allelic variation detected in the 53 non-redundant
proteomes. Sequence variation that destroys a predicted epitope is shown in red, while all variants shown in green were equally strong or only marginally less strong,
compared to the sequences shown in black. Gray blocks above the proteins indicate the position of experimentally proven B-cell epitopes, after Becquart et al. (2014).
differences between the US and West African populations, but
also found epitopes that are strongly conserved and recognized
in both populations, which could present optimal vaccine can-
didates. Experimental evidence for T-cell epitopes that are actu-
ally recognized by the host is only available frommousemodels.
Three predicted MHC class I epitopes for GP from ebolaviruses
(two for SUDV and two for Zaire ebolavirus) were able to induce
strong IFN-γ responses inmice (Wu et al. 2012). A vaccine trial in
mice with an epitope derived from NP, expressed in murine cy-
tomegalovirus, resulted in long-term expression of CD8+ T cells;
the epitope in question was located between amino acid 43 and
54; that region was not flagged in our analysis (Tsuda et al. 2011).
CONCLUSIONS
Ebolavirus genomes provide clues as to the relationship with
each other and reflect information that can be used to trace back
their likely geographical and temporal locations. In our opinion,
one of the most reliable methods for detection of Ebolavirus is
from its genome sequence. Novel sequencing methods can de-
tect the presence of ebolavirus within a few hours, which will
allow for rapid characterization of the virus. Further, with hun-
dreds of genomes, it is possible to measure the sequence vari-
ability, knowledge useful in the development of approaches to
help prevent the spread and recurrence of the outbreak.
EXPERIMENTAL PROCEDURES
Datasets
Ebolavirus genomes
On 28 October 2014, we downloaded all ebolavirus genomes
available from GenBank excluding all sequences with ‘from
Patent’ in the description and also removing all sequences less
than 200 bases in length. This resulted in 149 complete genomes
which included genomes representing the May 2014 outbreaks
in Sierra Leone (Gire et al. 2014) and genomes representing the
July 2014 outbreak in DRC (Maganga et al. 2014). Based on a cri-
terion of 100% sequence identify for matches that span a pair
of genome sequences to the extent that all coding sequences in
their entirety were included in the match using NUCmer pro-
gram from MUMmer (Kurtz et al. 2004), we reduced a dataset
of 149 ebolavirus genomes down to 84 ebolavirus genomes (60
Zaire, 10 Sudan, 8 Reston, 5 Bundibugyo, 1 Taı¨ Forest), We mod-
ified two genome sequences (KM034563, L11365) to estimate
missing segments using nearest neighbor sequences. The Gen-
Bank sequence KM034563 contains four runs of N’s of length
94, 45, 43 and 51. However, the four regions containing these
runs were so highly conserved (100% identity) in closely related
species that we felt justified in replacing the N’s with the most
likely bases. L11365, a Zaire sequence from 1976, is complete
up through the CDS for the first 54 amino acids of the final
L-protein, and differs from its nearest neighbor at 10 known
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locations, 4 SNPs and 6 indels. Because the L-protein was 100%
identical elsewhere in L11365’s four nearest neighbors, we added
this sequence into the L11365.
Ebolavirus proteomes
We reduced the 84 non-redundant Ebola genomes to 53 non-
redundant Ebola proteomes (34 Zaire, 7 Sudan, 8 Reston, 3
Bundibugyo, 1 Taı¨ Forest) based on the 100% amino acid se-
quence identity excluding the current DRC outbreak, KM519951
due to the lack of annotation of its mRNA in GenBank. Note that
the sequences filtered out had the same metadata (isolate, col-
lection date and country) as the one kept when they belonged
to the same cluster by 100% sequence identity. The resulting
Ebola datasets represented outbreaks in nine different coun-
tries, Guinea (GIN), Sierra Leone (SLE) and Coˆte d’Ivoire (COT) in
West Africa, Democratic Republic of Congo (DRC, formerly Zaire),
Gabon (GAB), Uganda (UGA), Sudan in Central Africa, Philippines
(PHI) and United States (USA) between 1976 and 2014.
Marburgvirus genomes and proteomes
On 28 October 2014, we downloaded all marburgvirus
genomes available from GenBank. This resulted in a dataset of
80 complete genomes, 73 of which had CDS features specified
from which complete proteomes could be determined.
Rooting phylogenetic trees
It is well known that rooting a tree of Zaire ebolaviruses using
any distantly related ebolavirus is problematic in the sense that
the branching pattern of Zaire ebolaviruses differs depending on
the deriving features; for example, using coding gene sequences
versus intergenic sequences changes the molecular evolution
story of the current outbreaks (Dudas and Rambaut 2014). With
different datasets of Zaire ebolaviruses, the root-to-tip regres-
sion analysis showed much better correlation between genetic
divergence and isolation date when the trees were rooted with
the 1976 outbreak (Carroll et al. 2013; Dudas and Rambaut 2014;
Gire et al. 2014). Thus, we rooted the Zaire ebolavirus tree in Fig. 4
and the two trees in Fig. S1 (Supporting Information) to the clade
of the earliest recorded outbreak in 1976.
Phylogeny construction
We investigated the molecular evolution of ebolaviruses based
on many different features, from complete genomes to individ-
ual proteins. The substitution models were identified based on
Bayesian Information Criterion (BIC) using jModelTest (Darriba
et al. 2012) for DNA sequences and ProtTest (Darriba et al. 2011)
for amino acid sequences. Table 1 lists the substitution models
used for the ebolavirus trees comparison presented in Fig. 4. The
GP and L Protein identified FLU models for influenza proteins as
the best model.
Repeating pattern distance
The RPD method examines the distances between short se-
quence motifs such as three or four nucleotide-long sequences
(e.g. GAC or GTAC). If several distances between such mo-
tifs and their order are shared between organisms, this is
used to provide evidence of an evolutionary relationship and
the quantitative similarity can be used to score evolutionary
distance.
Epitope selection
A set of epitopes with optimal coverage of both the different
Ebola strains and the HLA alleles prevalent in the populations
of interest (US and West Africa) was selected as follows.
HLA allele selection
HLA allele frequency data were obtained from the allele fre-
quency net database (Gonzalez-Galarza et al. 2011). A set of rel-
evant HLA alleles specific for the US and West Africa popula-
tions was chosen such that there was 95% population coverage
at each of the three HLA-A, HLA-B and HLA-DRB1 loci. For the
US, this led to the selection of 27 HLA-A, 58 HLA-B and 33 HLA-
DRB1 alleles. For West Africa, the numbers were 19, 31 and 20
(these allele sets are available in Table S2, Supporting Informa-
tion). For the HLA-DP and HLA-DQ loci, the allele combinations
recommended by the Immune Epitope Database were used (Kim
et al. 2012).
T-cell epitope selection
T-cell epitopes were predicted in the 53 ebolavirus genomes that
were non-redundant at the protein level. HLA alleles were used
as targets for the epitope predictions. HLA class I-restricted 9-
mer epitopes were predicted using NetMHCcons1.1 (Karosiene
et al. 2012) and NetChop3.1 C-terminal peptide processing algo-
rithm (Nielsen et al. 2005). HLA class II-restricted 15-mer epi-
topes were predicted using NetMHCIIpan3.0 (Karosiene et al.
2013). Epitope selection used both weak and strong binding
thresholds, default settings for HLA-I and proteasomal cleavage
and IEDB recommendations for HLA-II:
Weak—HLA-I: Peptides with a C-terminal cleavage score greater
than 0.5 and either a predicted binding affinity of less than
500 nM or a rank score ≤2%. HLA-II: Peptides with rank scores
≤ 10%.
Strong—HLA-I: Peptides with a predicted binding affinity of less
than 50 nMor a rank score≤0.5%. HLA-II: Peptideswith rank scores
≤2%.
The strong threshold produces the best binders for vaccine
candidates. However, when studying the natural immune re-
sponse, it is well recognized that a strong threshold is often
overly restrictive and filters out the virus-inactivating epitopes
onemay be looking for (Stranzl et al. 2010; Paul et al. 2013). Tables
of the top predicted epitopes are presented in the Supplemental
Material.
Candidate epitope selection
Each amino acid position in the ebolavirus proteome was given
an epitope score based on the number of epitopes overlapping
at that given position. The scores were weighted by allele fre-
quency, giving epitopes bound by prevalent MHC molecules a
larger contribution to the final epitope score. Separate scores
were calculated for MHC class I and class II.
Final epitope selection
Final epitope selections were based on calculated population
coverage for each candidate epitope using the PopCover method
(Buggert et al. 2012), as described by Schubert, Lund and Nielsen
(2013). Epitope tables can be found in the Table S1 (Supporting
Information).
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